 Kathleen Waugh
Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Islets of Langerhans | 10 | 2023 | 726 | 1.340 |
Why?
| | Diabetes Mellitus, Type 1 | 21 | 2023 | 3252 | 1.280 |
Why?
| | Autoantibodies | 17 | 2022 | 1346 | 0.940 |
Why?
| | Autoimmunity | 13 | 2023 | 813 | 0.900 |
Why?
| | Celiac Disease | 6 | 2022 | 264 | 0.840 |
Why?
| | Mass Screening | 6 | 2021 | 1004 | 0.390 |
Why?
| | Transglutaminases | 4 | 2021 | 142 | 0.370 |
Why?
| | Luminescent Measurements | 3 | 2021 | 74 | 0.360 |
Why?
| | Glutens | 2 | 2019 | 56 | 0.320 |
Why?
| | Child | 22 | 2023 | 18412 | 0.280 |
Why?
| | Inflammation | 1 | 2017 | 2479 | 0.270 |
Why?
| | Infant | 12 | 2022 | 7961 | 0.250 |
Why?
| | Blood Proteins | 2 | 2017 | 231 | 0.240 |
Why?
| | Electrochemical Techniques | 2 | 2021 | 45 | 0.220 |
Why?
| | Child, Preschool | 12 | 2021 | 9114 | 0.220 |
Why?
| | GTP-Binding Proteins | 2 | 2021 | 139 | 0.210 |
Why?
| | Disease Progression | 8 | 2022 | 2380 | 0.210 |
Why?
| | Insulins | 1 | 2022 | 32 | 0.190 |
Why?
| | Zinc Transporter 8 | 1 | 2021 | 86 | 0.190 |
Why?
| | Oxylipins | 1 | 2020 | 27 | 0.180 |
Why?
| | Virus Diseases | 1 | 2021 | 195 | 0.160 |
Why?
| | Genetic Predisposition to Disease | 3 | 2022 | 2086 | 0.150 |
Why?
| | Dietary Proteins | 1 | 2019 | 122 | 0.150 |
Why?
| | Genotype | 2 | 2020 | 1760 | 0.150 |
Why?
| | Autoantigens | 1 | 2021 | 396 | 0.150 |
Why?
| | High-Throughput Screening Assays | 1 | 2019 | 123 | 0.150 |
Why?
| | Humans | 28 | 2023 | 114674 | 0.150 |
Why?
| | Interferon-gamma | 1 | 2021 | 719 | 0.140 |
Why?
| | Male | 19 | 2021 | 55589 | 0.140 |
Why?
| | Adolescent | 12 | 2022 | 17841 | 0.140 |
Why?
| | Influenza, Human | 1 | 2022 | 546 | 0.140 |
Why?
| | Health Care Costs | 1 | 2020 | 381 | 0.140 |
Why?
| | Female | 18 | 2021 | 59499 | 0.130 |
Why?
| | Eating | 1 | 2019 | 344 | 0.130 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 382 | 0.130 |
Why?
| | DNA Methylation | 1 | 2020 | 495 | 0.130 |
Why?
| | Peptides | 1 | 2021 | 848 | 0.130 |
Why?
| | Prospective Studies | 6 | 2023 | 6219 | 0.130 |
Why?
| | Pediatrics | 2 | 2020 | 979 | 0.120 |
Why?
| | Biomarkers | 3 | 2021 | 3408 | 0.120 |
Why?
| | Follow-Up Studies | 5 | 2021 | 4411 | 0.120 |
Why?
| | Case-Control Studies | 2 | 2020 | 3003 | 0.110 |
Why?
| | Proteome | 1 | 2016 | 339 | 0.110 |
Why?
| | Diet | 1 | 2019 | 1080 | 0.100 |
Why?
| | Cytokines | 2 | 2017 | 1841 | 0.100 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2016 | 801 | 0.100 |
Why?
| | Oxidative Stress | 1 | 2017 | 1076 | 0.090 |
Why?
| | Toll-Like Receptors | 1 | 2012 | 167 | 0.090 |
Why?
| | Insulin | 1 | 2021 | 2079 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1518 | 0.090 |
Why?
| | Sensitivity and Specificity | 3 | 2022 | 1692 | 0.090 |
Why?
| | Risk Factors | 5 | 2023 | 8632 | 0.090 |
Why?
| | Interleukin-1beta | 1 | 2012 | 370 | 0.090 |
Why?
| | Insulin Antibodies | 2 | 2022 | 102 | 0.080 |
Why?
| | Interleukin-6 | 1 | 2012 | 676 | 0.080 |
Why?
| | Prognosis | 3 | 2021 | 3329 | 0.070 |
Why?
| | Proportional Hazards Models | 2 | 2019 | 1075 | 0.060 |
Why?
| | Longitudinal Studies | 2 | 2020 | 2387 | 0.050 |
Why?
| | Glycomics | 1 | 2022 | 7 | 0.050 |
Why?
| | Ascorbic Acid | 1 | 2023 | 110 | 0.050 |
Why?
| | Polysaccharides | 1 | 2022 | 78 | 0.050 |
Why?
| | Electrochemistry | 1 | 2021 | 79 | 0.050 |
Why?
| | Sciatic Nerve | 1 | 2002 | 56 | 0.050 |
Why?
| | Lipoprotein Lipase | 1 | 2002 | 54 | 0.050 |
Why?
| | Proteomics | 2 | 2017 | 836 | 0.050 |
Why?
| | China | 1 | 2021 | 161 | 0.050 |
Why?
| | Diagnostic Techniques, Radioisotope | 1 | 2021 | 8 | 0.050 |
Why?
| | Immunoglobulin D | 1 | 2021 | 27 | 0.050 |
Why?
| | Antigens, Viral | 1 | 2021 | 176 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2022 | 309 | 0.050 |
Why?
| | Serologic Tests | 1 | 2021 | 49 | 0.050 |
Why?
| | Adult | 5 | 2021 | 30546 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2021 | 75 | 0.040 |
Why?
| | Myelin Sheath | 1 | 2002 | 144 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2020 | 94 | 0.040 |
Why?
| | Fatty Acids, Omega-6 | 1 | 2020 | 45 | 0.040 |
Why?
| | Young Adult | 3 | 2021 | 10466 | 0.040 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 101 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 4408 | 0.040 |
Why?
| | Epitopes | 1 | 2021 | 435 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2021 | 166 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 439 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2021 | 246 | 0.040 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 196 | 0.040 |
Why?
| | Immunoglobulin E | 1 | 2021 | 314 | 0.040 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2020 | 122 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2020 | 217 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 316 | 0.040 |
Why?
| | Diet Surveys | 1 | 2019 | 78 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2022 | 615 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2021 | 520 | 0.040 |
Why?
| | Diabetic Ketoacidosis | 1 | 2020 | 159 | 0.040 |
Why?
| | Population Surveillance | 1 | 2020 | 392 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 544 | 0.040 |
Why?
| | Calcium | 1 | 2023 | 1108 | 0.040 |
Why?
| | Insulin-Secreting Cells | 1 | 2021 | 317 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2022 | 720 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 560 | 0.030 |
Why?
| | Radioimmunoassay | 1 | 2016 | 162 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2021 | 770 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2018 | 343 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 520 | 0.030 |
Why?
| | Glutamate Decarboxylase | 1 | 2016 | 160 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2018 | 362 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 520 | 0.030 |
Why?
| | Incidence | 1 | 2021 | 2313 | 0.030 |
Why?
| | HLA-DR Antigens | 1 | 2016 | 219 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2021 | 959 | 0.030 |
Why?
| | Macrophages | 1 | 2002 | 1262 | 0.030 |
Why?
| | Middle Aged | 3 | 2021 | 26735 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1737 | 0.030 |
Why?
| | Biopsy | 1 | 2016 | 1036 | 0.030 |
Why?
| | Body Mass Index | 1 | 2020 | 1958 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 1796 | 0.030 |
Why?
| | Hypoglycemic Agents | 1 | 2020 | 1013 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1430 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2015 | 740 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2019 | 2763 | 0.020 |
Why?
| | Cohort Studies | 1 | 2021 | 4895 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 2968 | 0.020 |
Why?
| | Exercise | 1 | 2022 | 1644 | 0.020 |
Why?
| | Transcriptome | 1 | 2016 | 725 | 0.020 |
Why?
| | Colorado | 1 | 2020 | 4099 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2012 | 493 | 0.020 |
Why?
| | Age Factors | 1 | 2016 | 2894 | 0.020 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2022 | 2096 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 6115 | 0.020 |
Why?
| | Mice | 1 | 2022 | 14869 | 0.020 |
Why?
| | United States | 1 | 2021 | 12182 | 0.020 |
Why?
| | Animals | 2 | 2022 | 31706 | 0.010 |
Why?
| | Aged | 1 | 2021 | 19073 | 0.010 |
Why?
| | Nerve Crush | 1 | 2002 | 4 | 0.010 |
Why?
| | Peripheral Nerves | 1 | 2002 | 64 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 4513 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2002 | 1629 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2002 | 2218 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2002 | 2553 | 0.010 |
Why?
| | Rats | 1 | 2002 | 4958 | 0.010 |
Why?
|
|
Waugh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|